Immuno Cure BioTech and PharmaJet have announced a collaboration to advance a novel HIV therapeutic DNA vaccine, ICVAX, using PharmaJet’s innovative Tropis needle-free injection system. The partnership was commemorated with a material transfer agreement signing ceremony at the BIO 2025 International Convention in Boston, USA.
The collaboration aims to evaluate the safety and immunogenicity of ICVAX delivered via PharmaJet’s Tropis device in a clinical study. ICVAX employs Immuno Cure’s patented PD-1-Enhanced DNA Vaccine technology to achieve sustained immune-mediated HIV-1 virological control without the need for antiretroviral therapy (ART).
The clinical study will be conducted at Prince of Wales Hospital in Hong Kong SAR, led by Professor Grace LUI from the Chinese University of Hong Kong. This collaborative effort involves Immuno Cure, CUHK, and the AIDS Institute of the University of Hong Kong, with partial funding from the Public Sector Trial Scheme of the Innovation and Technology Commission of the HKSAR Government.
Dr. Xia JIN, CEO of Immuno Cure, expressed enthusiasm about partnering with PharmaJet, stating that this collaboration advances needle-free vaccination solutions and accelerates ICVAX’s global commercialization potential. Mr. Dan MALLON, Senior Vice President of Corporate Development at PharmaJet, highlighted the potential of the Tropis intradermal delivery system to make a substantial impact for HIV patients.
HIV/AIDS remains a significant global health challenge, with over 39 million people living with HIV as of 2023. Current ART is effective in suppressing the virus but does not provide a cure, underscoring the need for effective immunotherapies like ICVAX.
Immuno Cure is a clinical-stage biotechnology group focused on developing innovative DNA medicines and antibody immunotherapies. PharmaJet specializes in needle-free injection technology, enhancing vaccine effectiveness and patient experience.
